2. Autocoids
⢠Derived from Greek w:
- Aut- Self
- Ak s- Healing substance or remedy
⢠Diverse substances produced by a wide
variety of cells in the body having
intense biological activity
Unique attribute f aut c id:
⢠They act locally (e.g. within
inflammat ry pckets) at the site o
f
synthesis & release.
3. ⢠They have also been calledâ as l cal
h rm nes'.
Differ from 'h rm nes' in 2 ways-
1. Hormones are produced by
specific cells
2. They are transp rted through
circulation to act on distant target
tissues.
4. The classical autac ids are- 5 types
A. Amine autac ids:
⢠Histamine, 5-Hydroxytryptamine
(Serotonin)
B. Lipid derived autac ids:
⢠Prostaglandins, Leukotrienes,
activating factor (PAF)
Platelet
5. C. Peptide autac ids:
⢠Plasma kinins (Bradykinin,
Angiotensin
Kallidin),
D. Cyt kines:
⢠interleukins, TNF-ι etc.
E. Several peptides:
⢠Like gastrin, somatostatin,
intestinal peptide and many
vasoactive
thers
7. HISTAMINE
⢠Histamine- 'tissue amineâ
L cati n:
1. Mast cell
⢠Mostly within storage Granules of
mast cells.
⢠Tissues rich in histamine are:
â skin
â gastric and intestinal mucosa
â lungs, liver and placenta.
Mast cell leukemia.jpg, Ayman
Qasrawi at English Wikipedia - Transferred
from en.wikipedia to Commons. Public Domain.
https://commons.wikimedia.org/wiki/File:Mast_c
ell_leukemia.jpg#/media/File:Mast_cell_leukemi
a.jpg Created: 17 November 2008.
8. 2. Nn- mast cell histamine occurs in brain, epidermis, gastric
mucosa and growing regions.
⢠It is also present in blood, body secretions, venoms and
pathological fluids.
9. Difference between mast cell and nn mast cell histamine
⢠T urnver of mast cell histamine is sl w
⢠while that of non-mast cell histamine is fast
10. Q&A
1. Among local and systemic which one is
the action of autocoids?
2. Name autocoid which is called as
tissue amine.
3. Give example of lipid derived
autocoid.
1
1
11. Synthesis, st rage and destructi n
⢠Histamine is β-imidaz lylethylamine.
⢠Synthesized locally from - - - > amin
histidine
acid
⢠Degraded rapidly by - - - > oxidation &
methylation.
12. ⢠In mast cells
histamine (positively charged)
within intracellular granules there is acidic protein & heparin
(negatively charged).
13. ⢠Release f Histamine: Exocytosis
Sdium ions in e.c.f. exchange with histamine to release it free.
⢠Cntr l f histamine release: intracellular cAMP
inhibits histamine release.
⢠Histamine is inactive rally liver degrades all histamine
14. Histamine R:
Histaminergic R were classified by Asch and Schild (1966) into
â H1, H2 and H3
â H3 R
Serves primarily as an auto receptor
control histamine release from neurons in brain
16. Triple Acti n f histamine: Injected intradermally:
Elicits the triple response consisting of:
I. Red spt: due to intense capillary dilatation
II. Wheal: due to exudation of fluid from capillaries & venules.
I I I . Flare: i.e. redness in the surr undings area due to arteriole
dilatation mediated by axon reflex.
20. At the end f this e- learning sessi n yu are able t âŚ
ďąDiscuss pharmacological action of
histamine.
ďąExplain its pathological role.
ďąClassify anti-histaminic drugs.
2
1
22. PHARMACOLOGICAL ACTIONS
⢠On s.c. injectin-
- Flushing, increased HR & CO with little r n
fall in BP
⢠Rapid i.v. injectin - - - > causes fall in BP
â Increase - - - - > capillary permeability
23. 2. Heart
⢠I s lated heart of guinea pig-
â rate as well as force of contraction
is increased.
25. 4. Intestine:
⢠Large dses
contractions
- - - > increases intestinal
causes abdominal cramps and colic
26. 5. Uterus:
⢠Guinea pig uterus is contracted while that
of rat is relaxed
⢠Human uterus - not much affected
Sm th muscle c ntracti n â H 1 response.
In few instances - - > H2 mediated relaxation is also seen
27. Q&A
1. What is effect of histamine on smaller blood
vessels?
2. Why asthmatic patients are more sensitive to
histamine?
3.Which histaminergic
muscle contraction?
receptors mediate smooth
2
8
28. 4. Glands (GIT)
⢠H2-receptors mediate activati n
ATPase pump.
H-K.
Marked increase in gastric secretion (acid &
pepsin)
29. 5. Sens ry nerve endings:
⢠Itching- injected i.v. or intracutaneously.
⢠Higher concentrations injected more deeply
cause pain.
reflect the capacity of histamine to stimulate
nerve endings.
Aut n mic ganglia and adrenal medulla
⢠Stimulation release of Adrenaline
secondary rise in BP.
30. d brain barrier - - > no central
6. CNS
⢠Des nt penetrate bl
effects (On IV)
⢠However, intracerebro-ventricular administration
produces:
- Rise in BP
- cardiac stimulation
- behavioral arousal
- hypothermia
- vomiting & ADH release
Mediated thr ugh b th H1 and H2 R.
32. 2. Allergic phen men n:
⢠Mediate Immediate type
- Urticaria
- Angioedema
- Bronchoconstriction
- Anaphylactic shock
f hypersensitivity reactin-
H1 antag nists are effective
33. 3. As transmitter
⢠Act as a afferent transmitter
Initiates the sensation of itch and pain at sensory nerve ending
4. Inflammatin
⢠Implicated as a mediator of vasodilatation & inflammation.
34. 5. T issue gr wth and repair
⢠Play an essential role in the process of growth & repair.
6. Headache
⢠Implicated in certain vascular headaches
⢠n cnclusive evidence
40. At the end f this e- learning sessi n yu are able t âŚ
ďą Discuss pharmacological action of H1 anti-
histamine.
ďą Explain its side effects and symptoms of acute
overdose.
ďą Discuss indications for use of anti-histaminic
drugs.
4
1
41. PHARMACOLOGICAL ACTIONS
1. Antag nism f histamine
⢠can effectively block Histamine induced
effect:
- Bronchoconstriction
- Cntracti n of intestinal & other smooth
muscle - - - > Larger blood vessel
- Triple resp nse - - - > wheal, flare and itch.
- Release f Adrenaline from adrenal
medulla
42. 2. Anti-allergic acti n
⢠Many manifestations of immediate
hypersensitivity - - > are suppressed.
ďź Urticaria, itching and angio-edema - - - - - > are well
controlled.
ďź Anaphylactic fall in BP - - - - - - > partially
prevented.
ďź Asthma in man - - - - - > practically unaffected
43. 3.CNS
⢠The older antihistamines - - - - > variable degree of CNS
depression.
Depend on the ability of drug to penetrate BBB & its
affinity f r the central H1 receptors.
44. 3.CNS
⢠Individuals also experience stimulant effects - - - - - >
restlessness & insomnia.
⢠Excitement and convulsions - - - - > seen at toxic doses.
⢠The second generation anti-histaminics - - - - >
practically non sedating.
46. 5. Local anaesthetic
⢠Pheniramine: have strong while others have weak
membrane stabilizing property.
6. BP
⢠Most anti-histaminics cause a fall in BP on i.v.
injection (direct smooth muscle relaxation).
not evident on oral administration.
47. Q&A
1. Name allergic reactions controlled by H1-
antihistaminics?
2. Which factors determine degree of CNS depression
produced by older anti-histaminics?
3.Among older and second generation anti-histaminic
drugs which one are non sedative in nature?
4
8
48. PHARMACOKINETICS
⢠The classical H1 antihistaminics are well absorbed
from oral and parenteral routes
⢠Metab lized in the liver and excreted in urine.
⢠They are widely distributed in the body and enter
brain.
⢠The newer cmp unds penetrate brain poorly.
⢠Durati n f acti n of most agents is 4.4 hours, except
meclizine, I oratadine, cetirizine and fexofenadine
which act for 12-24 hrs or more.
49. S IDE EFFECT S AND T OXI CI T Y
ď Sedation,
concentration
Diminished alertness and
ď Motor incoordination
ď Fatigue
ď Tendency to fall a sleep.
⢠Cauti ned
â not to operate motor vehicles or machinery
⢠Alc h l synergizes
50. ďź Dryness of mouth
ďź Alteration of bowel movement
ďź Urinary hesitancy and blurring of vision
antich linergic pr perty
51. ⢠L cal applicati n - - - > can cause contact
dermatitis.
⢠Acute
excitation
muscular
flushing,
verd se produces central
- - - > tremors,
incoordination,
hallucinations,
convulsions,
hypotension, fever and some
other features of bellad nna pis ning.
⢠Death is due to
cardiovascular failure.
- - - > respiratory and
53. ⢠The sec nd generati n anti-histaminics (SGAs) are defined as those H1-
receptor blockers
Marketed after 1980 & have ne r m re f the fll wing pr perties :
- Higher H1 selectivity - - - > no anti-cholinergic SE.
- Absence of - - - > CNS depressant property.
- Additi nal anti-allergic mechanisms:
- Action on leukotrienes
- or having antiplatelet activating effect.
54. Advantages:
⢠Not impairing psychomotor
performance - - - > (driving need not
be contraindicated)
⢠No sleepiness
⢠Do not p tentiate alcohol or
benzodiazepines.
55. f 2nd
⢠The principal indicati ns
generati n anti-histaminics:
(i) Allergicrhinitis, cnjunctivitis, hay
fever & pllin sis-
- Control sneezing, runny but nt
bl cked
eyes.
nse & red watering itchy
56. (ii) Urticaria, derm graphism, at pic eczema.
Dermatographism on forearm of a 19 year old college student taken at Cornell College. JAguayo18 - Own
work. CC BY-SA 4.0. File:Physical Urticaria Dermatographism.jpg. Created: 24 April 2016
57. (iii) Acute allergic reacti ns to drugs and foods.
They have p r anti-pruritic, antiemetic and Anti-tussive actions.
61. At the end f this e- learning sessi n yu are able t âŚ
ďą Discuss pharmacological action of cetirizine.
ďą Give uses of anti-histaminics.
ďą Explain salient features of H2 & H3 anti-
histaminics.
ďą Discuss synthesis and destruction of 5-HT
ďą Explain different types of serotonin receptors.
6
2
62. Cetirizine
⢠It is a metab lite of hydroxyzine
with marked affinity f r peripheral
H1 R.
⢠Penetrates the brain poorly
⢠It is nt metab liz ed
Drug I nteracti n:
⢠P tentiate arrhythmias when given
along with erythromycin/ketoconazole.
63. ⢠I t Inhibits release f
â Histamine
â Cytotoxic mediators
⢠I t attains high & longer lasting concentration in skin
May be resp nsible for superior efficacy in urticaria
/atopic dermatitis
Indicatins:
⢠It is indicated in upper respiratory allergies,
pollinosis, urticaria and atopic dermatitis
⢠Also used as adjuvant in seasonal asthma.
64. Uses f anti-histaminics
1. Allergic disorders
2. Antipruritic action
3. Common cold
4. Motion sickness
5. Vertigo
6. Pre-anaesthetic medicati n - Promethazine has been used for
its antich linergic and sedative pr perties.
7. Cugh: eg chlorpheniramine, diphenhydramine and promethazine
65. 8. Parkinsonism:
Promethazine and some other - - - > provide mild
symptomatic relief in early cases of
parkinsonism.
9. As sedative, hypnotic, anxiolytic
antihistamines with CNS depressant action - - - >
especially in children.
67. H2-antihistaminics:
⢠Cimetidine was introduced in 1977
⢠Other widely used H2 antihistaminics:
â Ranitidine, famotidine, roxatidine
⢠They are primarily used in:
- peptic ulcer
- gastric hypersecretory state
69. H3 antag nist
⢠Selective H3 antagonist ex. thi peramide has been
produced
not found any clinical utility.
70. Q&A
1. Give example of drug which potentiate arrhythmia
when given along with cetrizine.
2. Enlist few indications for the use of cetirizine?
3.Enlist few uses anti-histaminic drugs?
4. Justify why cetrizine has superior efficacy in
urticaria /atopic dermatitis.
7
1
72. 5-HYDROXYTRYPTAMINE
(5-HT, Serotonin)
⢠Ser tnin
Vas c nstrict r (Appeared when bl d cl tted).
⢠Enteramine
The sm th muscle cntracting substance present in
(enterochromaffin cells of gut mucosa).
72
73. L cati n:
⢠About 90% f b dy's cntent
intestines
⢠The rest is in platelets and brain
⢠It is also found in scorpion sting
73
- - - > localized in the
& plants (banana,
⢠Widely distributed in invertebrates
pear, pineapple, tomato, stinging nettle).
77. At the end f this e- learning sessi n yu are able t âŚ
ďąDiscuss synthesis and degradation of 5-
HT
ďąExplain different types of serotonin
receptors.
ďąDiscuss its Pharmacological action & role
in pathophysiology.
7
8
78. SYNTHESIS AND DEGRADATION
⢠5-HT is β-aminoethyl-5-hydroxy indole.
Degradati n:
⢠Primarily by MAO (MAO-A)
⢠And to a small extent by a dehydrogenase.
78
79. SEROTONERGIC (5-HT) RECEPTORS AND THEIR MECHANISM
⢠Gaddum and Picarelli (1957) classified 5-HT R into musculotropic (D type) &
neurotropic (M type)
⢠Four families of 5 - HT R (5-HT1 to 5-HT4)
⢠5 - HT R (except 5 - HT3) are G protein coupled receptors
⢠5 - HT-3 - - - - > Ligand gated cation (Na, K-) channel
which on activation elicits fast depolarization
79
80. Pharmac l gical acti n:
CVS
⢠Arteries are
â cnstricted
â dilated (through release of EDRF)
⢠Releases Adr from adrenal medulla
Evokes CVS reflexes.
⢠Larger arteries and veins - - - > constricted.
⢠Is lated heart - - - > stimulation
CONSTRICTION / DILATATION OF ARTERIES
AND STIMULATION OF HEART
80
81. TRIPHESIC RESPONSE OF 5HT
⢠Seen on i.v. injection of 5 - HT in animals.
â Early sharp fall in BP
â Brief rise in BP
â Prolonged fall in BP
81
82. Sm th muscles
GIT:
⢠Several subtypes of 5-HT R are present
in the gut.
Increases peristalsis Diarrhea
82
85. Nerve endings and adrenal medulla:
⢠Afferent nerve endings are activated - - - > tingling, pricking
sensation & pain.
Respirati n:
⢠brief stimulation of respiration
hyperventilation
⢠Large d ses can cause transient apnea
85
87. ďą CNS
⢠Poorly crosses bl d-brain barrier.
Direct injecti n in the brain pr duces
⢠Sleepiness
⢠Changes in body temperature
⢠Hunger
⢠Variety of behavioral effects.
87
88. Q&A
1. What is the precursor of 5-HT.
2. Name 2 enzymes which metabolizes 5-HT.
3. Give pharmacological action of 5-HT on gastric
gland.
4. What is triphasic response of 5-HT?
8
9
89. PATHO PHYSIOLOGICAL ROLES
Neur transmitter:
⢠5-HT is a neurotransmitter in the brain
in affective
Imbalance may result
disrders & schiz phrenia
89
90. Precurs r f melat nin:
⢠Act as precurs r of melatonin
Regulate
rhythm).
Act on pineal gland
bi l gical cl ck (circadian
Neur endcrine functin:
⢠Regulated by serotonergic mechanism.
90
91. Nausea and vomiting
⢠cytotoxic drugs or radiotherapy
Evoked nausea & vomiting by its action
on 5-HT3 R in the gut
91
92. Migraine
⢠Initiate
migraine
the vas c nstrict r phase of
Methylsergide (5-HT
effective prophylactic
antagonist) is an
& sumatriptan (5-HT1B/1D agonist) can
control an attack.
92
93. ďą Hem stasis
Platelets release 5-HT at the site of
injury to blood vessel.
Accelerates platelet aggregation &
clot formation.
93
95. Hypertensi n
⢠Increased responsiveness to 5-HT - - - > demonstrated in hypertensive
patients.
⢠Ketanserin (5HT R antag nist) - - - > antihypertensive property.
Intestinal m tility
⢠Regulate peristalsis and local reflexes in the gut.
Carcin id syndr me
⢠Bowel hypermotility and bronchoconstriction in carcinoid is due to 5-HT.
95
99. At the end f this e- learning sessi n yu are able t âŚ
ďąClassify 5-HT antagonists.
ďąExplain pharmacology of cyproheptadine,
ketanserin & Ergotamine.
ďąDiscuss adverse effects and contraindications
of 5-HT receptor antagonist.
1
0
0
100. 5 - HT ANTAGONISTS CLASSIFICATION
A. Erg t derivatives: (Ergotamine, LSD, 2-
bromo LSD, methylsergide)
B. Adrenergic Îą bl ckers: (phenobenzamine)
C. Antihistaminic: (cyproheptadine, cinnarizine)
D. Chl rpr mazine
E. Mrphine etc.
⢠These are nonselective
several other receptors.
and interact with
101
102. ⢠Used in
â allergies
â And for antipruritic action
⢠Rec mmended in children - - - > to increase
appetite
⢠P r eaters to promote weight gain.
An acti n n growth
may be responsible.
hormone secretion
102
103. ⢠Control intestinal manifestations of - - - >
carcin id and pst-gastrect my
Anti-5HT Acti n may be responsible
⢠SE:
- drowsiness
- dry mouth
- confusion
- ataxia
- weight gain.
103
104. Ketanserin
â˘It has selective 5 - HT2 R bl cking property
â˘antag nized 5 - HT induced
- platelet aggregation
- contraction of airway smooth muscle
⢠does not antagonize contraction of guinea
pig ileum or rat stomach
â˘Use: Effective antihypertensive
104
105. ERGOT ALKALOIDS
â˘Ergot is obtained from a fungus - - > Claviceps
purpurea
â˘Epidemics of erg t pis ning (erg tism):- - - >
due to consumption of contaminated grains
Dry gangrene
become black
f hands and feet - - - >
106
It
Drgnu23 at English Wikipedia - Drgnu23 - Taken in
my practice.CC BY-SA 3.0.
https://commons.wikimedia.org/wiki/File:Dry_gange
ne_4th_toe.jpg#/media/File:Dry_gangene_4th_toe.j
pg. Dry gangene 4th toe.jpg. Created: 27 December
2004
106. Pharmac l gical acti n:
⢠Miscarriages - - - > in women & cattle.
⢠A c nvulsi n - - - > in some patients.
⢠It c ntains a h st
substances:-
- alkaloids
- LSD
- histamine
- Ach
- tyramine
f pharmacologically active
- and other amines, sterols etc.
106
107. Natural erg t alkal ids:
â˘Tetracyclic indole containing compounds (derivatives of lysergic
acid).
Chemical structure of Lysergic acid. NadirSH - Own work.
https://commons.wikimedia.org/wiki/File:Lysergic_acid.svg
#/media/File:Lysergic_acid.svg .CC BY-SA 4.0. Lysergic
acid.svg. Created: 21 April 2020
107
109. Q&A
1. Give example of adrenergic blocking drug with 5-HT
receptor antagonistic activity.
2. Enlist few clinical uses of Cyproheptadine.
3.Which 5-HT antagonist drug can
Miscarriages.
4. What is chemical composition of ergotoxine?
induce
1
1
0
110. Pharmacl gical Acti ns:
Erg tamine:
⢠Partial ag nist & antag nist - - - > ι adrenergic & all subtypes of 5-HT1 &
5-HT2 R
â˘It pr duces
â Sustained vasoconstriction
â Visceral smooth muscle - - - > contraction
â Vasomotor centre - - - > dĂŠpression
â Antagonizes the action of - - - > NA and 5-HT on smooth muscles.
110
111. ⢠Potent - - > emetic (thr ugh CTZ)
⢠Moderately potent - - > oxytocic.
⢠At high d ses - - - > CNS stimulation
⢠On chronic exposure - - - > ergot poisoning
vasoconstriction accompanied by damage to capillary endothelium - - - >
- thrombosis
- vascular stasis and gangrene
111
112. Dihydr erg tamine (DHE):
⢠Hydr genati n of ergotamine
reduces 5HT and Îą-adrenergic agonistic actions
but enhances Îąâ R blocking property.
⢠I t is a less potent vasoconstrictor
⢠I t is a weaker emetic & oxytocic
⢠but has some antidopaminergic action.
112
113. Dihydr-oergotoxine (Mixture)
⢠a more potent ι blocker.
⢠In the brain it having:
⢠A variety of partial agonistic/
antagonistic actions on 5 - HT R
⢠Causes enhancement of - - - > Ach release
in cerebral cortex
treatment of dementia
113
114. Pharmac kinetics
⢠Oral bioavailability of amino acid erg t alkal ids and their hydr genatec
derivatives is p r (< 7%) due to slow and incomplete absorption as well as high
first pass-metabolism.
⢠Bi availability is better after sublingual and rectal administration
⢠Ergotamine is sequestrated in tissues - produces longer lasting actions compared
to its plasma half life of 2 hours.
⢠Ergot alkaloid-effectively cross blood-brain barrier.
114
116. These drugs are c ntraindicated in presence f
⢠ischemic heart disease
⢠peripheral vascular disease
⢠hypertension
⢠pregnancy
⢠liver and kidney diseases
116